(San Antonio) Privately held San Antonio company, Rapamycin Holdings,  has secured exclusive rights to market a formula designed by the Health Science Center and Southwest Research Institute to break down in the intestines instead of the stomach so patients can better absorb it.

A second version of the university’s formula, dubbed eRapaNP2g, has significant implications for veterinary care, showing promise in treating feline chronic gingivostomatitis, a painful oral condition in domestic cats.